<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196075</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2017.616</org_study_id>
    <nct_id>NCT04196075</nct_id>
  </id_info>
  <brief_title>The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer</brief_title>
  <acronym>AP</acronym>
  <official_title>The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on
      palliative management of patients with advanced or metastatic esophageal cancer. A total of
      30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited
      for the trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic relief and quality of life after AP</measure>
    <time_frame>4 months</time_frame>
    <description>Symptomatic relief of Dysphagia and quality of life after treatment Dysphagia measured by Dysphagia score Quality of Life measured by EORTC-QLQ-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difficulty to swallow</measure>
    <time_frame>4 months</time_frame>
    <description>Difficulty to swallow by dysphagia grade 0 = able to eat normal diet / no dysphagia.
= able to swallow some solid foods
= able to swallow only semi solid foods
= able to swallow liquids only
= unable to swallow anything / total dysphagia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Median Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Rate of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AP side effects</measure>
    <time_frame>4 months</time_frame>
    <description>Side effects related to AP including
Gastrointestinal upset
Nausea and Vomiting
Allergy
Diarrhoea
Abdominal pain
Dizziness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Squamous Cell Carcinoma of Esophagus</condition>
  <arm_group>
    <arm_group_label>Andrographis Paniculata treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Andrographis Paniculata</intervention_name>
    <description>AP as palliative treatment</description>
    <arm_group_label>Andrographis Paniculata treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged over 18

          2. Locally advanced esophageal cancer with invasion or adherent to surrounding organs
             including trachea, recurrent laryngeal nerves and descending aorta;

          3. Presence of distant metastasis;

          4. Extensive lymph node metastasis to beyond surgical therapy

        Exclusion Criteria:

          1. Patients who cannot receive palliative stenting for dysphagia or under other
             conventional treatment including chemotherapy or chemoradiotherapy

          2. Patients who are not willing to receive Chinese herbal medicines

          3. Patients who do not consent for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip WY Chiu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip WY Chiu, MD</last_name>
    <phone>35053952</phone>
    <email>philipchiu@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Man Yee Yung</last_name>
    <phone>35052956</phone>
    <email>myyung@surgery.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <state>Outside Of US &amp; Canada</state>
        <zip>00000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip WY Chiu, MD</last_name>
      <phone>85235053952</phone>
      <email>philipchiu@surgery.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Man Yee Yung</last_name>
      <phone>85235052956</phone>
      <email>myyung@surgery.cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Philip Wai Yan Chiu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Andrographolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

